Treatment and Clinical Characteristics in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) using Talazoparib and Enzalutamide (tala+enza) Combination Therapy

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  ENZALUTAMIDE

  TALAZOPARIB
• Anatomical Therapeutic Chemical (ATC) code:
  (L02BB04) enzalutamide

  enzalutamide

  (L01XK04) talazoparib

  talazoparib
• Medical condition to be studied:
  Prostate cancer
• Additional medical condition(s):
  Metastatic Castration-Resistant Prostate Cancer

Population studied

• Short description of the study population:
  Adult, male PC patients with prescription(s) for tala+enza combination treatment on or after June 20, ; 2023 will be identified and followed until the end of follow-up, which is the earliest of date of death or the end of data availability. The source population comprises diverse real-world patients who have received care within the MGB healthcare system, as captured in the RPDR database.

Study design details

• Study design:
  Adult, male PC patients with prescription(s) for tala+enza combination treatment on or after June 20, 2023 will be identified and followed until the end of follow-up, which is the earliest of date of death or the end of data availability.
• Main study objective:
  Longitudinal data from the MGB RPDR will be used to address the study objectives. The MGB RPDR is drawn from the EPIC EHR system of teaching hospitals affiliated with Harvard Medical School.; For more details, please refer to the protocol.